000272838 001__ 272838
000272838 005__ 20241028164615.0
000272838 0247_ $$2doi$$a10.1007/s00702-024-02796-w
000272838 0247_ $$2pmid$$apmid:38976044
000272838 0247_ $$2pmc$$apmc:PMC11489248
000272838 0247_ $$2ISSN$$a0375-9245
000272838 0247_ $$2ISSN$$a0022-3026
000272838 0247_ $$2ISSN$$a0300-9564
000272838 0247_ $$2ISSN$$a1435-1463
000272838 037__ $$aDZNE-2024-01256
000272838 041__ $$aEnglish
000272838 082__ $$a610
000272838 1001_ $$0P:(DE-2719)9003154$$aBode, Merle$$b0$$eFirst author$$udzne
000272838 245__ $$aCognition and Activity of Daily Living Function in people with Parkinson's disease.
000272838 260__ $$aWien [u.a.]$$bSpringer$$c2024
000272838 3367_ $$2DRIVER$$aarticle
000272838 3367_ $$2DataCite$$aOutput Types/Journal article
000272838 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1729589021_23954$$xReview Article
000272838 3367_ $$2BibTeX$$aARTICLE
000272838 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272838 3367_ $$00$$2EndNote$$aJournal Article
000272838 520__ $$aThe ability to perform activities of daily living (ADL) function is a multifaceted construct that reflects functionality in different daily life situations. The loss of ADL function due to cognitive impairment is the core feature for the diagnosis of Parkinson's disease dementia (PDD). In contrast to Alzheimer's disease, ADL impairment in PD can be compromised by various factors, including motor and non-motor aspects. This narrative review summarizes the current state of knowledge on the association of cognition and ADL function in people with PD and introduces the concept of 'cognitive ADL' impairment for those problems in everyday life that are associated with cognitive deterioration as their primary cause. Assessment of cognitive ADL impairment is challenging because self-ratings, informant-ratings, and performance-based assessments seldomly differentiate between 'cognitive' and 'motor' aspects of ADL. ADL function in PD is related to multiple cognitive domains, with attention, executive function, and memory being particularly relevant. Cognitive ADL impairment is characterized by behavioral anomalies such as trial-and-error behavior or task step omissions, and is associated with lower engagement in everyday behaviors, as suggested by physical activity levels and prolonged sedentary behavior. First evidence shows that physical and multi-domain interventions may improve ADL function, in general, but the evidence is confounded by motor aspects. Large multicenter randomized controlled trials with cognitive ADL function as primary outcome are needed to investigate which pharmacological and non-pharmacological interventions can effectively prevent or delay deterioration of cognitive ADL function, and ultimately the progression and conversion to PDD.
000272838 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000272838 588__ $$aDataset connected to DataCite
000272838 650_7 $$2Other$$aActivities of daily living
000272838 650_7 $$2Other$$aCognition
000272838 650_7 $$2Other$$aNeuropsychology
000272838 650_7 $$2Other$$aParkinson’s disease
000272838 650_7 $$2Other$$aPhysical activity
000272838 650_7 $$2Other$$aSedentary behavior
000272838 650_2 $$2MeSH$$aHumans
000272838 650_2 $$2MeSH$$aParkinson Disease: physiopathology
000272838 650_2 $$2MeSH$$aParkinson Disease: complications
000272838 650_2 $$2MeSH$$aParkinson Disease: psychology
000272838 650_2 $$2MeSH$$aActivities of Daily Living
000272838 650_2 $$2MeSH$$aCognitive Dysfunction: physiopathology
000272838 650_2 $$2MeSH$$aCognitive Dysfunction: etiology
000272838 7001_ $$00000-0001-8603-2545$$aKalbe, Elke$$b1
000272838 7001_ $$0P:(DE-2719)2109499$$aLiepelt-Scarfone, Inga$$b2$$eLast author
000272838 773__ $$0PERI:(DE-600)1481655-6$$a10.1007/s00702-024-02796-w$$gVol. 131, no. 10, p. 1159 - 1186$$n10$$p1159 - 1186$$tJournal of neural transmission$$v131$$x0375-9245$$y2024
000272838 8564_ $$uhttps://pub.dzne.de/record/272838/files/DZNE-2024-01256.pdf$$yOpenAccess
000272838 8564_ $$uhttps://pub.dzne.de/record/272838/files/DZNE-2024-01256.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272838 909CO $$ooai:pub.dzne.de:272838$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000272838 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003154$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000272838 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2109499$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000272838 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000272838 9141_ $$y2024
000272838 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000272838 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000272838 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000272838 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000272838 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000272838 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURAL TRANSM : 2022$$d2023-10-21
000272838 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000272838 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000272838 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000272838 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000272838 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-21
000272838 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272838 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000272838 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000272838 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000272838 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000272838 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x0
000272838 980__ $$ajournal
000272838 980__ $$aVDB
000272838 980__ $$aUNRESTRICTED
000272838 980__ $$aI:(DE-2719)1210000
000272838 9801_ $$aFullTexts